RPL17 and breast cancer: In the context of our breast cancer study, the observed upregulation of ANXA1 in immune cells of PD‐1 nonresponders, coupled with its overall downregulation in breast cancer tissues, could indicate a complex interplay where the tumor microenvironment either co‐opts or is overwhelmed by ANXA1's pro‐resolving signals, potentially contributing to an immunosuppressive milieu despite ANXA1's inherent anti‐inflammatory properties.